New Age Alpha Advisors LLC Takes $1.06 Million Position in Stryker Co. (NYSE:SYK)

New Age Alpha Advisors LLC purchased a new stake in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,952 shares of the medical technology company's stock, valued at approximately $1,063,000.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Providence Capital Advisors LLC acquired a new position in shares of Stryker during the 4th quarter worth $4,902,000. Norges Bank acquired a new position in Stryker during the fourth quarter worth about $1,710,744,000. Rockbridge Investment Management LCC bought a new position in shares of Stryker in the fourth quarter worth about $385,000. AssuredPartners Investment Advisors LLC bought a new stake in shares of Stryker during the 4th quarter valued at approximately $407,000. Finally, NEOS Investment Management LLC increased its position in Stryker by 27.6% during the 4th quarter. NEOS Investment Management LLC now owns 21,361 shares of the medical technology company's stock worth $7,691,000 after purchasing an additional 4,619 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. Truist Financial raised their price objective on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a report on Thursday, January 30th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Finally, Citigroup restated a "buy" rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Remove Ads

Stryker Stock Down 2.5 %

SYK stock traded down $9.34 during mid-day trading on Thursday, reaching $368.12. 3,306,021 shares of the company traded hands, compared to its average volume of 1,304,839. The stock has a market cap of $140.51 billion, a price-to-earnings ratio of 47.44, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm's 50 day moving average price is $383.16 and its 200 day moving average price is $374.45. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company earned $3.46 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.50% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.